Abstract | BACKGROUND: METHODS: DISCUSSION: There is an urgent need to study and validate regimens such as new hormonal agents that may add benefit to castration with an acceptable safety profile. We aim to evaluate if apalutamide in monotherapy or in combination with AAP is an effective and safety hormonal treatment that can spare patients of androgen deprivation therapy. TRIAL REGISTRATION: This trial was registered in ClinicalTrials.gov on October 16, 2017, under Identifier: NCT02867020.
|
Authors | Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia Dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R S Nunes Filho, Facundo Zaffaroni, Carlos Barrios, André Fay |
Journal | BMC cancer
(BMC Cancer)
Vol. 19
Issue 1
Pg. 487
(May 23 2019)
ISSN: 1471-2407 [Electronic] England |
PMID | 31122212
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Androgen Receptor Antagonists
- Antineoplastic Agents, Hormonal
- Thiohydantoins
- apalutamide
- Goserelin
- Testosterone
- Abiraterone Acetate
- Prednisone
|
Topics |
- Abiraterone Acetate
(administration & dosage, therapeutic use)
- Adenocarcinoma
(drug therapy)
- Androgen Receptor Antagonists
(administration & dosage, therapeutic use)
- Antineoplastic Agents, Hormonal
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
- Disease-Free Survival
- Goserelin
(administration & dosage, therapeutic use)
- Humans
- Male
- Patient Reported Outcome Measures
- Prednisone
(administration & dosage, therapeutic use)
- Prostatic Neoplasms, Castration-Resistant
(drug therapy)
- Quality of Life
- Testosterone
(blood)
- Thiohydantoins
(administration & dosage, therapeutic use)
- Treatment Outcome
|